Common Contracts

AMENDED AND RESTATED SUBLICENSE AGREEMENT

Sublicense Agreement • November 7th, 2017 • Keryx Biopharmaceuticals Inc • Pharmaceutical preparations • New York

• Contract Type
  Sublicense Agreement
• Filed
  November 7th, 2017
• Company
  Keryx Biopharmaceuticals Inc
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

THIS AMENDED AND RESTATED SUBLICENSE AGREEMENT (the “Agreement”), effective this 8th day of June, 2009 (the “Effective Date”), by and between KERYX BIOPHARMACEUTICALS, INC., with offices at 750 Lexington Avenue, 20th Floor, New York, NY 10022, U.S.A. (“Keryx” or “Sublicensor”) and JAPAN TOBACCO INC., with offices at JT Building, 2-1, Toranomon 2-Chome, Minato-ku, Tokyo 105-8422, Japan (“JT”) and TORII PHARMACEUTICAL CO., LTD., with offices at Torii Nihonbashi Bldg., 4-1, Nihonbashi-Honcho 3-chome, Chuo-ku, Tokyo 103-8439, Japan (“TORII”) (JT and TORII collectively referred to herein as “Sublicensee”);

AMENDED AND RESTATED SUBLICENSE AGREEMENT

Sublicense Agreement • August 12th, 2009 • Keryx Biopharmaceuticals Inc • Pharmaceutical preparations • New York

• Contract Type
  Sublicense Agreement
• Filed
  August 12th, 2009
• Company
  Keryx Biopharmaceuticals Inc
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

THIS AMENDED AND RESTATED SUBLICENSE AGREEMENT (the “Agreement”), effective this 8th day of June, 2009 (the “Effective Date”), by and between KERYX BIOPHARMACEUTICALS, INC., with offices at 750 Lexington Avenue, 20th Floor, New York, NY 10022, U.S.A. (“Keryx” or “Sublicensor”) and JAPAN TOBACCO INC., with offices at JT Building, 2-1, Toranomon 2-Chome, Minato-ku, Tokyo 105-8422, Japan (“JT”) and TORII PHARMACEUTICAL CO., LTD., with offices at Torii Nihonbashi Bldg., 4-1, Nihonbashi-Honcho 3-chome, Chuo-ku, Tokyo 103-8439, Japan (“TORII”) (JT and TORII collectively referred to herein as “Sublicensee”);

SUBLICENSE AGREEMENT

Sublicense Agreement • March 27th, 2008 • Keryx Biopharmaceuticals Inc • Pharmaceutical preparations • New York

• Contract Type
  Sublicense Agreement
• Filed
  March 27th, 2008
• Company
  Keryx Biopharmaceuticals Inc
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

THIS SUBLICENSE AGREEMENT (the “Agreement”), effective as of this 26th day of September, 2007 (the “Effective Date”), by and between KERYX BIOPHARMACEUTICALS, INC., with offices at 750 Lexington Avenue, New York, NY 10022, U.S.A. (“Keryx” or “Sublicensor”) and JAPAN TOBACCO INC., with offices at JT Building, 2-1, Toranomon 2-Chome, Minato-ku, Tokyo 105-8422, Japan (“JT”) and TORII PHARMACEUTICAL CO., LTD., with offices at Torii Nihonbashi Bldg., 4-1, Nihonbashi-Honcho 3-chome, Chuo-ku, Tokyo 103-8439, Japan (“TORII”) (JT and TORII collectively referred to herein as “Sublicensee”);

SUBLICENSE AGREEMENT

Sublicense Agreement • November 9th, 2007 • Keryx Biopharmaceuticals Inc • Pharmaceutical preparations • New York

• Contract Type
  Sublicense Agreement
• Filed
  November 9th, 2007
• Company
  Keryx Biopharmaceuticals Inc
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

THIS SUBLICENSE AGREEMENT (the “Agreement”), effective as of this 26th day of September, 2007 (the “Effective Date”), by and between KERYX BIOPHARMACEUTICALS, INC., with offices at 750 Lexington Avenue, New York, NY 10022, U.S.A. (“Keryx” or “Sublicensor”) and JAPAN TOBACCO INC., with offices at JT Building, 2-1, Toranomon 2-Chome, Minato-ku, Tokyo 105-8422, Japan (“JT”) and TORII PHARMACEUTICAL CO., LTD., with offices at Torii Nihonbashi Bldg., 4-1, Nihonbashi-Honcho 3-chome, Chuo-ku, Tokyo 103-8439, Japan (“TORII”) (JT and TORII collectively referred to herein as “Sublicensee”);